Gilead defends Truvada pricing during House hearing

Chairman and CEO Daniel O'Day defended Gilead's pricing of HIV PrEP drug Truvada at a congressional hearing Thursday.

Democrats led by House Oversight and Reform Committee Chair Elijah Cummings (D-Md.) pressed O'Day on the price of Truvada emtricitabine/tenofovir in the U.S. compared with other countries, noting that one pill costs $70 in the U.S. and $7 in Australia. In response, O'Day said the difference in list prices was due in part to generic competition outside the U.S.